These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 37065845)

  • 1. Catastrophic antiphospholipid syndrome in an immune thrombocytopenia patient treated with avatrombopag.
    Van de Vondel S; Vandenbriele C; Gheysens G; Verhamme P; Janssens A
    Res Pract Thromb Haemost; 2023 Mar; 7(3):100125. PubMed ID: 37065845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Avatrombopag: A Review in Thrombocytopenia.
    Markham A
    Drugs; 2021 Nov; 81(16):1905-1913. PubMed ID: 34709601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An evaluation of avatrombopag for the treatment of thrombocytopenia.
    Virk ZM; Kuter DJ; Al-Samkari H
    Expert Opin Pharmacother; 2021 Feb; 22(3):273-280. PubMed ID: 33095074
    [No Abstract]   [Full Text] [Related]  

  • 4. An updated evaluation of avatrombopag for the treatment of chronic immune thrombocytopenia.
    Song AB; Al-Samkari H
    Expert Rev Clin Immunol; 2022 Aug; 18(8):783-791. PubMed ID: 35793401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study.
    Al-Samkari H; Jiang D; Gernsheimer T; Liebman H; Lee S; Wojdyla M; Vredenburg M; Cuker A
    Br J Haematol; 2022 May; 197(3):359-366. PubMed ID: 35179784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Additional efficacy analysis of avatrombopag phase III data for the treatment of adults with immune thrombocytopenia.
    Jain S; Gernsheimer T; Kolodny S; Bernheisel C; Vredenburg M; Panch SR
    Platelets; 2023 Dec; 34(1):2195016. PubMed ID: 37013676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag.
    Kuter DJ
    Blood Rev; 2022 May; 53():100909. PubMed ID: 34815110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Avatrombopag for the Treatment of Adult Patients with Chronic Immune Thrombocytopenia (cITP): Focus on Patient Selection and Perspectives.
    Tsykunova G; Ghanima W
    Ther Clin Risk Manag; 2022; 18():273-286. PubMed ID: 35386180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Catastrophic antiphospholipid syndrome in lupus-associated immune thrombocytopenia treated with eltrombopag A case series and literature review.
    Garra W; Carmi O; Kivity S; Levy Y
    Medicine (Baltimore); 2023 Feb; 102(6):e32949. PubMed ID: 36820549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Avatrombopag for the Treatment of Immune Thrombocytopenia and Periprocedural Thrombocytopenia Associated With Chronic Liver Disease.
    Tran TB; Downing L; Elmes JB; Arnall JR; Moore DC
    J Pharm Pract; 2024 Feb; 37(1):184-189. PubMed ID: 36113085
    [No Abstract]   [Full Text] [Related]  

  • 11. Avatrombopag for the treatment of immune thrombocytopenia and thrombocytopenia of chronic liver disease.
    Cheloff AZ; Al-Samkari H
    J Blood Med; 2019; 10():313-321. PubMed ID: 31565009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Avatrombopag increases platelet count but not platelet activation in patients with thrombocytopenia resulting from liver disease.
    Michelson AD; Smolensky Koganov E; Forde EE; Carmichael SL; Frelinger AL
    J Thromb Haemost; 2018 Dec; 16(12):2515-2519. PubMed ID: 30264918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased microvesicle-associated thrombin generation in patients with immune thrombocytopenia after initiation of thrombopoietin receptor agonists.
    Garabet L; Ghanima W; Hellum M; Sandset PM; Bussel JB; Tran H; Henriksson CE
    Platelets; 2020; 31(3):322-328. PubMed ID: 31280643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombopoietin receptor agonists for the treatment of primary immune thrombocytopenia: a meta-analysis and systematic review.
    Birocchi S; Podda GM; Manzoni M; Casazza G; Cattaneo M
    Platelets; 2021 Feb; 32(2):216-226. PubMed ID: 32281449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for Pharmacists.
    Gilreath J; Lo M; Bubalo J
    Drugs; 2021 Jul; 81(11):1285-1305. PubMed ID: 34160821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Avatrombopag for the treatment of immune thrombocytopenia.
    Długosz-Danecka M; Zdziarska J; Jurczak W
    Expert Rev Clin Immunol; 2019 Apr; 15(4):327-339. PubMed ID: 30799645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombopoietin receptor agonist for treatment of immune thrombocytopenia in pregnancy: a narrative review.
    Agarwal N; Mangla A
    Ther Adv Hematol; 2021; 12():20406207211001139. PubMed ID: 33796239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus.
    Pulanić D; Bátorová A; Bodó I; Červinek L; Ionita I; Lissitchkov T; Melikyan A; Podolak-Dawidziak M
    Ann Hematol; 2023 Apr; 102(4):715-727. PubMed ID: 36826482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two cases of thrombosis in patients with antiphospholipid antibodies during treatment of immune thrombocytopenia with romiplostim, a thrombopoietin receptor agonist.
    LaMoreaux B; Barbar-Smiley F; Ardoin S; Madhoun H
    Semin Arthritis Rheum; 2016 Feb; 45(4):e10-2. PubMed ID: 26329147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia.
    Jurczak W; Chojnowski K; Mayer J; Krawczyk K; Jamieson BD; Tian W; Allen LF
    Br J Haematol; 2018 Nov; 183(3):479-490. PubMed ID: 30191972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.